The pathogenesis of Alzheimer's disease. Is amyloid beta-protein the beginning or the end?
A central issue in Alzheimer's disease research is whether amyloid beta-protein (A beta) is a cause or effect of the pathogenic process. Several independent lines of evidence argue for causality, although human clinical trials may be required to finally settle the issue.
Yankner
B A
BA
Department of Neurology, Harvard Medical School and Children's Hospital, Boston, Massachusetts 02115, USA. Yankner@A1.tch.harvard.edu
D000544:Alzheimer Disease / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D001921:Brain / Q000378:metabolism / Q000473:pathology; D006801:Humans
D016229:Amyloid beta-Peptides